Heron Therapeutics (HRTX): FDA Priority Review for HTX-011 Seen as 'Significant Positive' - Needham & Company
Tweet Send to a Friend
Needham & Company analyst Serge Belanger reiterated a Buy rating and $66 price target on Heron Therapeutics (NASDAQ: HRTX) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
